Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection

Perrotta, Fabio Massimo; Chino, Vittorio; Allocca, Valentino; D’Agnano, Vito; Bortolotto, Chandra; Bianco, Andrea; Corsico, Angelo Guido; Stella, Giulia Maria

doi:10.1080/17476348.2022.2145948

Cited by 4 publications

(1 citation statement)

References 166 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In experimental studies with mice, PD-L1 expression was noted to be higher in injury-activated alveolar epithelial cells and in human donor samples with end-stage IPF [58 ▪ ], suggesting that disinhibition of immune cells might exacerbate this injured tissue. Though IPF and lung cancer are not often thought to share common genetic pathways, several genes that drive inflammation and fibrosis in IPF are also overexpressed in lung cancer, including TGF-β1, IL-1 receptor alpha, IL-4, IL-8, and others [59,60 ▪ ]. The shared genetic landscape of IPF and NSCLC has led to the use of antifibrotics to treat NSCLC, though evidence of efficacy is yet lacking [61,62 ▪ ].…”

Section: Preexisting Interstitial Lung Diseasementioning

confidence: 99%

Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease

Azhar

Abrencillo

Gandhi

et al. 2023

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of reviewImmune checkpoint inhibitors (ICIs) are the frontline of therapy for most cancers. Although ICIs are sometimes considered to be less harmful than systemic chemotherapies, ICIs may cause immune-related adverse events, which are cases of off-target inflammation in healthy tissues. Pneumonitis, an immune-related adverse event, is the leading cause of therapy-related mortality with ICIs. The aim of this review is to discuss how preexisting interstitial lung disease (ILD) and thoracic radiation increase the risk for ICI-pneumonitis. We discuss potential mechanisms of lung injury and how pneumonitis may impact cancer treatments.Recent findingsPreexisting ILD and thoracic radiation are major risk factors for ICI-pneumonitis. The mechanisms of injury are still not fully understood but may involve the same inflammatory and profibrotic cytokines as those seen in sporadic ILD. Thoracic radiation increases the risk for ICI-pneumonitis and may synergize with preexisting ILD to worsen toxicity.SummaryPreexisting ILD and thoracic radiation may increase the risk for the future development of ICI-pneumonitis. However, while these should not preclude potentially life-saving immunotherapy, in some cases, an alternative treatment strategy may be advisable. A multidisciplinary approach is required involving oncologists, pulmonologists, and radiation oncologists to guide in the selection of cancer treatment and in the diagnosis and treatment of pneumonitis.

show abstract

Section: Preexisting Interstitial Lung Diseasementioning

confidence: 99%

Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease

Azhar

Abrencillo

Gandhi

et al. 2023

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders

D’Agnano,

Mariniello,

Pagliaro

et al. 2024

Drugs

Self Cite

View full text Add to dashboard Cite

The sirtuin family is a heterogeneous group of proteins that play a critical role in many cellular activities. Several degenerative diseases have recently been linked to aberrant sirtuin expression and activity because of the involvement of sirtuins in maintaining cell longevity and their putative antiaging function. Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis associated with systemic autoimmune disorders are severe diseases characterized by premature and accelerated exhaustion and failure of alveolar type II cells combined with aberrant activation of fibroblast proliferative pathways leading to dramatic destruction of lung architecture. The mechanisms underlying alveolar type II cell exhaustion in these disorders are not fully understood. In this review, we have focused on the role of sirtuins in the pathogenesis of idiopathic and secondary pulmonary fibrosis and their potential as biomarkers in the diagnosis and management of fibrotic interstitial lung diseases.

show abstract

Endoscopic treatment of endobronchial carcinoid: technical considerations and experience in interventional pulmonology

GUARINO,

CESARO,

LA CERRA

et al. 2024

Minerva Respir Med

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection

Cited by 4 publications

References 166 publications

Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease

Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease

Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders

Endoscopic treatment of endobronchial carcinoid: technical considerations and experience in interventional pulmonology

Contact Info

Product

Resources

About